Clinical Differences between Men and Women with Psoriatic Arthritis: Relevance of the Analysis of Genes and Polymorphisms in the Major Histocompatibility Complex Region and of the Age at Onset of Psoriasis

Table 3

Distribution of most significant markers in men and women with PsA.

(a)

Marker	PsA females: 55	Female controls: 55
HLA-C*06	31 (56.4%); OR: 6.6 (2.7–16.1), 𝑃𝑐=0.0001	9 (16.4%)
HLA-C*07	27 (49%); OR: 2.8 (1.3–6.3), 𝑃𝑐=0.01	14 (25.5%)
TNF-308A	25 (45.5%); OR: 3.0 (1.3–6.9), 𝑃𝑐=0.009	12 (22%)
MICA-A9	33 (60%); OR: 3.1 (1.4–6.7), 𝑃𝑐=0.004	18 (32.7%)
HLA-B*27	15 (27.3%); OR: 4.8 (1.5–15.5), 𝑃𝑐=0.01	4 (7.3%)

(b)

Marker	PsA males: 55	Male controls: 55
HLA-C*06	31 (56.4%); OR: 5.8 (2.4–13.8), 𝑃𝑐=0.0001	10 (18.2%)
MICA-A9	33 (60%); OR: 4.0 (1.8–8.9), 𝑃𝑐=0.001	15 (27.3%)
HLA-B*27	20 (36.4%); OR: 7.3 (2.3–23.2), 𝑃𝑐=0.0004	4 (7.3%)